This site is intended for Healthcare professionals.
×

FDA approves new drug for instant treatment of acute migraine


FDA approves new drug for instant treatment of acute migraine
Food and Drug Administration has approved a new drug for treating acute migraine in adults.

The U.S. Food and Drug Administration today approved lasmiditan tablets for the acute treatment of migraine with or without aura in adults. The new drug, Reyvow is not indicated for the preventive treatment of migraine.

The Food and Drug Administration has granted the approval of Reyvow to Eli Lilly and Company.

Migraine headache pain is often described as an intense throbbing or pulsing pain in one area of the head. Migraine is three times more common in women than in men and affects more than 10% of people worldwide. According to Mayo Clinic a migraine can cause severe throbbing pain or a pulsing sensation, usually on one side of the head. It’s often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Migraine attacks can last for hours to days, and the pain can be so severe that it interferes with your daily activities, symptom known as an aura occurs before or with the headache. An aura can include visual disturbances, such as flashes of light or blind spots, or other disturbances, such as tingling on one side of the face or in an arm or leg and difficulty speaking.

................................ Advertisement ................................

Medications can help prevent some migraines and make them less painful. The right medicines, combined with self-help remedies and lifestyle changes, might help

Migraines, which often begin in childhood, adolescence or early adulthood, can progress through four stages: prodrome, aura, attack and post-drome. Not everyone who has migraines goes through all stages.

................................ Advertisement ................................

“Reyvow is a new option for the acute treatment of migraine, a painful condition that affects one in seven Americans,” said Nick Kozauer, M.D., acting deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “We know that the migraine community is keenly interested in additional treatment options, and we remain committed to continuing to work with stakeholders to promote the development of new therapies for the acute and preventive treatment of migraine.”

The effectiveness of Reyvow for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials. A total of 3,177 adult patients with a history of migraine with and without aura treated a migraine attack with Reyvow in these studies. In both studies, the percentages of patients whose pain resolved and whose most bothersome migraine symptom (nausea, light sensitivity, or sound sensitivity) resolved two hours after treatment were significantly greater among patients receiving Reyvow at all doses compared to those receiving placebo. Although patients were allowed to take a rescue medication two hours after taking Reyvow, opioids, barbiturates, triptans and ergots were not allowed within 24 hours of the study drug’s administration. Twenty-two percent of patients were taking preventive medication for migraine.

There is a risk of driving impairment while taking Reyvow. Patients are advised not to drive or operate machinery for at least eight hours after taking Reyvow, even if they feel well enough to do so. Patients who cannot follow this advice are advised not to take Reyvow. The drug causes central nervous system (CNS) depression, including dizziness and sedation. It should be used with caution if taken in combination with alcohol or other CNS depressants.

The most common side effects that patients in the clinical trials reported were dizziness, fatigue, paresthesia, and sedation.




Source: Eli Lilly and Company

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted
  1. It will be boon if Lasmiditan will allay the suffering of migraine patients.
    Hope soon this medicine may be available in India also

................................ Advertisement ................................